MAPT and Alzheimer disease: Mollenhauer et al.[24] found that CSF mean alpha-synuclein levels and not total tau or Aβ42 levels differentiated Parkinson's disease and MSA from neurological controls (70% sensitivity, 53% specificity), whereas a combination of alpha-synuclein, tau protein, and age discriminated between synucleinopathies and neurological controls and Alzheimer's disease [area under the curve (AUC) 0.908].